Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
Johns Hopkins Singapore, City of Singapore, Singapore.
Future Oncol. 2016 Dec;12(23):2755-2764. doi: 10.2217/fon-2016-0068. Epub 2016 Aug 23.
Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents.
MATERIALS & METHODS: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines.
Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33).
Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.
顺铂或卡铂联合放化疗是头颈部鳞癌确定性治疗的选择之一。本研究旨在进行荟萃分析以比较这两种铂类药物。
我们根据 Cochrane 综述指南对 1990 年至 2015 年 4 月 17 日期间的英文文献进行了系统检索。
60 项研究中有 5 项符合纳入标准，共纳入 491 例患者。两组患者的缓解率无差异。顺铂的全身活性优于卡铂，但差异无统计学意义；5 年生存率：分别为 30%和 27%（p = 0.33）。
尽管使用顺铂的治疗结果有改善趋势，但卡铂也具有活性，是治疗患者的合理选择。
